United Therapeutics Corporation
UTHRHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, United Therapeutics Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United. The $23.64B market capitalization puts UTHR squarely in large-cap range for its industry. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Market Cap
$23.64B
Beta
0.59
P/E (TTM)
20.58
P/E (Fwd)
17.52
EPS (TTM)
$27.05
EPS (Fwd)
$31.77
ROE
20.3%
ROA
12.6%
Cash
$2.15B
Total Debt
$0
Free CF
$566.4M
52W Change
71.1%
Annual Financials
Cash vs Debt
United Therapeutics Corporation reports $2.15B in cash and $0 in total debt. The company generates $566.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 20.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 12.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.94B (2022) to $3.18B (2025), reflecting a 64% increase over the period.
With a beta below 0.7, United Therapeutics Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence United Therapeutics Corporation's trajectory.